Evidence map›Paper›PMID 32266317›Full record

ArticleArchives of clinical infectious diseases2019

Drug resistance patterns in HIV patients with virologic failure in Iran.

Seyed Ahmad Seyed Alinaghi, Mehrnaz Rasoolinejad, Zeinab Najafi, Omid Dadras, Ehsan Malekianzadeh, Ali Mirzazadeh

Open access · diamondAbstract read
In one paragraph

Article in Archives of clinical infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Seyed Ahmad Seyed AlinaghiIranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
Mehrnaz RasoolinejadIranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
Zeinab NajafiIranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
Omid DadrasDepartment of Global Health and Socioepidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ehsan MalekianzadehDezful University of Medical Sciences, Dezful, Iran.
Ali MirzazadehHIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Kerman University of Medical Sciences, Kerman, Iran.
Tehran University of Medical Sciences · IRDezful University of Medical Sciences · IRIranian Institute for Health Sciences Research · IRKerman University of Medical Sciences · IRKyoto University · JP

Funding

Int'l Traineeships in AIDS Prevention Studies (ITAPS)R25MH064712 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LINDAN, CHRISTINA P · 2002 to 2018
$3.4M
International Traineeships in AIDS Prevention Studies (ITAPS)R25MH123256 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTINA P LINDAN · 2020 to 2026
$1.8M
NIMH NIH HHS R25 MH064712NIMH NIH HHS R25 MH123256
6 · The paper itself

Abstract

We reviewed the medical charts of 1,700 patients diagnosed with HIV who referred to a central HIV clinic in Tehran between 2004 and 2017. Participants who had a viral load of > 200 copies/mL after six months or more on antiretroviral therapy (ART) were grouped as virologic failure (VF). We assessed the demographic characteristics, diagnosis date, first ART regimen, and resistance to various ART drugs. Out of 1,700 patients, 72 (4.2%) had a treatment failure. Among those with treatment failure, 51.3% were on zidovudine + lamivudine + efavirenz, 13.9% were on tenofovir + lamivudine + lopinavir/ritonavir, and 12.5% were on tenofovir + emtricitabine + efavirenz. In patients with treatment failure, the highest resistance was to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) combination (44.4%). In these patients, resistance to tenofovir (one of the NRTIs) was 29.1%. The highest treatment failure was observed among patients treated with nevirapine (NVP) and efavirenz (EFV)-based regimen. Our findings suggest that protease inhibitors should be considered as first-line drugs in ART regimens in VF patients in Iran.

Indexed as

antiretroviral therapyHIV/AIDSIranVirologic Failure

Identifiers

PMID32266317
PMCPMC7138207
OpenAlexW2999841033

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.